ENGN — enGene Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1980845 ·
Quebec, Canada
Last close
$1.62
Market Cap
$108.52M
52W High
$9.00
52W Low
$1.40
ADV30
2,860,473
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jan 2026 | 0 | — | -31,185,000 | -29,752,000 | 337,113,000 | 36,613,000 | 55,567,000 |
| Oct 2025 | 0 | — | -39,481,000 | -37,880,000 | 221,468,000 | 50,152,000 | 53,758,000 |
| Jul 2025 | 0 | — | -29,947,000 | -28,991,000 | 245,550,000 | 32,623,000 | 44,878,000 |
| Apr 2025 | 0 | — | -27,124,000 | -25,815,000 | 266,651,000 | 57,545,000 | 39,360,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-102,446,000
Investing CF
$-66,471,000
Financing CF
$143,183,000
CapEx
$-1,339,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-401,784,000
Inventory
—
Receivables
$1,197,000
ST Investments
$239,335,000
EBIT TTM
$-119,482,000
Pretax Income TTM
$-122,456,000
Interest Exp TTM
$2,974,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -123,165,000 | -117,302,000 | 221,468,000 | 53,758,000 | — | -99,239,000 |
| Oct 2024 | 0 | -62,297,000 | -55,142,000 | 311,173,000 | 38,561,000 | — | -48,281,000 |
| Oct 2023 | 0 | -26,060,000 | -99,917,000 | 86,959,000 | 14,473,000 | — | -24,743,000 |
| Oct 2022 | 0 | -19,427,000 | -24,462,000 | 23,909,000 | 47,405,000 | — | -17,592,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.99
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGTX | COGNITION THERAPEUTICS INC | $108.29M | $1.21 | — |
| CRDF | Cardiff Oncology, Inc. | $105.29M | $1.54 | — |
| KLRS | Kalaris Therapeutics, Inc. | $103.02M | $4.33 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $100.28M | $1.75 | — |
| CRDL | Cardiol Therapeutics Inc. | $118.73M | $1.03 | — |
News headlines (Yahoo Finance, 1h cache)
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-06-15 13:00 · Yahoo
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations
2026-05-11 01:11 · Yahoo
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
2026-05-08 23:05 · Yahoo
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?
2026-05-08 21:27 · Yahoo
enGene Therapeutics hit by analyst downgrades as drug data disappoints
2026-05-08 15:41 · Yahoo
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
2026-05-07 11:00 · Yahoo
enGene Announces Name Change to enGene Therapeutics Inc.
2026-04-07 12:00 · Yahoo
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
2026-03-15 21:33 · Yahoo
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
2026-03-15 20:37 · Yahoo
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
2026-03-15 19:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.